Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05504863
Other study ID # R-2111-07169
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 11, 2022
Est. completion date January 2026

Study information

Verified date November 2023
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

As a follow-up to the RAPIDIRON Trial (NCT05358509), this study will follow the previously randomized mothers as well as their offspring after birth to assess neurodevelopmental, hematologic, and health outcomes. The study's overarching goal is to determine if the offspring born to RAPIDIRON Trial mothers in the intravenous iron groups, compared to the oral iron group, will achieve superior neurodevelopment, iron stores, and growth at specific time points during the first three years of life. Differences will be assessed between offspring based on the iron deficiency anemia (IDA) treatment of the mother.


Description:

The RAPIDIRON-KIDS Study has two primary hypotheses: 1. Infants born to RAPIDIRON Trial maternal participants from the intravenous (IV) iron arms will have higher hemoglobin and ferritin levels at birth (determined by cord blood) and at 4 months of age compared to infants born to mothers in the oral arm; and 2. Offspring born to RAPIDIRON Trial participants who received IV iron treatment will have higher developmental quotients (DQs) on the cognitive domain of the Bayley Scales of Infant Development (BSID) at 2 years of age compared to offspring born to RAPIDIRON Trial participants given oral iron treatment. The specific aims of this study are as follows: - To provide evidence that a single-dose of IV iron (either ferric carboxymaltose or iron isomaltoside, also known as ferric derisomaltose) given to pregnant women in the second trimester during the RAPIDIRON Trial will prove more effective for prevention of neonatal and postnatal iron deficiency in the offspring than the oral iron given to pregnant women per the parent trial protocol - To assess if the offspring of women in the parent trial IV iron arms have better neurodevelopmental outcomes compared to the offspring of women treated with oral iron; and - To determine longer-term hematologic effects in previously randomized mothers by obtaining ongoing hematologic indices, documented history of transfusion and hospitalization, and quality of life based on the use of a validated instrument. This study will recruit pregnant mothers currently participating in the RAPIDIRON Trial, who will be approached to give consent for themselves and their offspring for participation in the RAPIDIRON-KIDS Study. Participation in RAPIDIRON-KIDS will involve assessments at birth, 6 weeks, 4 months, 12 months, 24 months, and 36 months of age. In addition to iron status, anthropometry, and questionnaires relating to child feeding and maternal quality of life, the following neurobehavioral tests will be utilized to assess the offspring at various timepoints: Preferential Looking Test, Ages & Stages Questionnaire 3, Bayley Scales of Infant Development, Behavioral Rating Scale, India Scale for Assessment of Autism, and the Child Behavior Checklist for Ages 1.5-5. Please see the protocol for additional details.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 538
Est. completion date January 2026
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Informed consent of the RAPIDIRON Trial participant for their study inclusion and that of their offspring for the RAPIDIRON-KIDS Study - Expressed intent of the RAPIDIRON Trial participant to remain in the designated Karnataka research are for delivery and during the follow-up period for the RAPIDIRON-KIDS Study to enable participation in study visits - For the offspring - live-born singleton infants of Karnataka maternal participants randomized and treated in the RAPIDIRON Trial, if consent is provided by the mother Exclusion Criteria: - Unwillingness of maternal participant to provide RAPIDIRON-KIDS Study consent for herself and her offspring

Study Design


Intervention

Drug:
Ferric carboxymaltose
As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
Iron isomaltoside
As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
Ferric Sulfate
As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.

Locations

Country Name City State
India S. Nijalingappa Medical College Bagalkot Karnataka
India Jawaharlal Nehru Medical College Belgaum Karnataka
India Raichur Institute of Medical Sciences Raichur Karnataka

Sponsors (4)

Lead Sponsor Collaborator
Thomas Jefferson University Jawaharlal Nehru Medical College, Raichur Institute of Medical Sciences, S. Nijalingappa Medical College

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Other Offspring hospitalization Incidence of offspring hospitalization Birth to 3 years of age
Other Maternal hospitalization Incidence of maternal hospitalization Birth to 3 years
Other Maternal transfusions Incidence of maternal blood transfusions Birth to 3 years
Primary Offspring hemoglobin Offspring hemoglobin concentration in g/dL Birth
Primary Offspring hemoglobin Offspring hemoglobin concentration in g/dL 4 months of age
Primary Offspring ferritin Offspring serum ferritin concentration in ng/mL Birth
Primary Offspring ferritin Offspring serum ferritin concentration in ng/mL 4 months of age
Primary Cognitive Domain of Bayley Scales of Infant Development (BSID) Developmental quotient (DQ) on the cognitive domain of the Bayley Scales of Infant Development (BSID), conducted at 24 months of age. The Cognitive Domain of the BSID-IV contains 81 items, each item with a minimum score of 0 and a maximum score of 2. A lower score is a bad outcome and a higher score is a good outcome. 24 months of age
Secondary Offspring hemoglobin Offspring hemoglobin concentration in g/dL 12 months of age
Secondary Offspring ferritin Offspring serum ferritin concentration in ng/mL 12 months of age
Secondary Preferential Looking Time Performance on Preferential Looking Time assessment - scored as the percentage of time spent looking at the novel object during the test phase 4 and 12 months of age
Secondary Motor and language domains of the Bayley Scales of Infant Development (BSID) Developmental quotient (DQ) on the motor and language domains of the Bayley Scales of Infant Development (BSID), conducted at 24 months of age. The motor domain of the BSID-IV contains 79 items, and the language domain contains 104 items. Minimum score on each item is 0, maximum score is 2. A lower score is a bad outcome and a higher score is a good outcome. 24 months of age
Secondary Bayley Scales of Infant Development (BSID) Developmental quotients (DQs) on all domains of the Bayley Scales of Infant Development (BSID), conducted at 36 months of age. There are 5 domains, each many items. Each item has a minimum score of 0 and a maximum score of 2. A lower score is a bad outcome and a higher score is a good outcome. 36 months of age
Secondary Behavior Rating Scale Score on the Behavior Rating Scale, as coded from a video recording undergoing the Bayley Scales of Infant Development (BSID). Each child is rated across nine behavioral domains. The minimum score in each domain is 0 and the maximum score is 5, with higher scores indicating more optimal behaviors. 24 months of age
Secondary Ages & Stages Questionnaire 3 Accepted and validated screening tool for neurodevelopment. Minimum score of 0, maximum score of 60. Lower score is a bad outcome, higher score is a good outcome. 12 months of age
Secondary Child Behavior Checklist for Ages 1.5-5 A parent-report questionnaire assessing internalizing and externalizing behaviors. Standardized t-scores will result, with a mean of 50 and standard deviation of 10. Higher scores indicate more symptoms (emotional/behavioral) and a worse outcome. 24 and 36 months of age
Secondary India Scale of Assessment for Autism A standardized screening tool for autism, validated for the Indian population. 40 items are rated from 1 to 5, with a higher score indicating increasing severity. 36 months of age
Secondary Offspring weight Offspring weight measured in kg 4, 12, 24, and 36 months of age
Secondary Offspring height Offspring height measured in cm 6 weeks, 4, 12, 24, and 36 months of age
Secondary Offspring head circumference Offspring head circumference measured in cm Birth, 4, 12, 24, and 36 months of age
Secondary Infant and Young Child Feeding Practices A composite questionnaire used to measure feeding practices based upon breastfeeding, dietary diversity, meal frequency, iron supplementation, and iron-fortified foods. Birth, 6 weeks, 4, 12, and 24 months of age
Secondary Maternal hemoglobin concentration Maternal hemoglobin concentration measured in g/dL 4, 12, and 24 month visits
Secondary Maternal ferritin Maternal serum ferritin concentration in ng/mL 4, 12, and 24 month visits
Secondary Maternal well-being/quality of life Maternal well-being/quality of life, as measured by the World Health Organization Disability Assessment Schedule II (WHODAS-II). Uses 36 items to measure health and disability across six domains of life - cognitive, mobility, self care, relationship, life activities, and participation. Each item is given a score from 0 to 4, and all item scores are summed. Higher scores mean worse outcomes and higher disability status. 4 and 12 month visits
See also
  Status Clinical Trial Phase
Completed NCT05207956 - App for Strengthening Services In Specialized Therapeutic Support N/A
Completed NCT03286621 - Development of Eye-tracking Based Markers for Autism in Young Children
Completed NCT02608333 - Efficiency of Early Intervention for Autism Spectrum Disorder N/A
Recruiting NCT05935722 - Evaluation of a Home-based Parenting Support Program: Parenting Young Children N/A
Active, not recruiting NCT06259539 - A YouTube Curriculum for Children With Autism and Obesity N/A
Active, not recruiting NCT06303791 - Digital-based Psychosocial Intervention for Parents of Children With Neurodevelopmental Disorders N/A
Enrolling by invitation NCT05017779 - A Hybrid Effectiveness-implementation Trial of a High School-based Executive Function Treatment for Autistic Youth N/A
Completed NCT04772898 - Effectiveness of a 6-week Hippotherapy Program in Children With Autism Spectrum Disorder N/A
Recruiting NCT04987541 - The Therapeutic Effect of TBS Stimulation on Emotion Regulation in Autism Spectrum Disorder N/A
Completed NCT04308915 - Mobile-based Games for Cognitive Training in Children With Neurodevelopmental Disorders N/A
Completed NCT06038435 - The Effect of Cognitive Orientation Approach on Daily Occupational Performance With Autism Spectrum Disorder N/A
Terminated NCT04049981 - Investigation of Mechanisms of Action in Superpower Glass Phase 1/Phase 2
Completed NCT03693313 - The Effect of CrossFit Kids on Social Skills in Children With Autism Spectrum Disorder (CrossFit KAMP) N/A
Recruiting NCT04107064 - Achieving Steady Work Among Adults With Autism Through Specialized Employment Program N/A
Recruiting NCT03812068 - Parent-mediated Developmental Behavioral Intervention N/A
Completed NCT03206996 - Exposure Therapy for Auditory Sensitivity in Autism N/A
Completed NCT02299700 - Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder N/A
Completed NCT03422016 - Electroretinogram in Autistic Spectrum Disorders
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Recruiting NCT05114538 - Improving the Part C Early Intervention Service Delivery System for Children With ASD N/A